Pageltra (Eltrombopag)

Eltrombopag, the active ingredient in Pageltra, is a thrombopoietin receptor agonist presented as a tablet for oral use. It stimulates platelet production and is used to manage low platelet counts in certain chronic conditions. GNH USA supplies Pageltra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

GNH USA supplies Pageltra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Eltrombopag acts on the thrombopoietin pathway to increase platelet production in several hematologic disorders.

- Chronic immune thrombocytopenia (ITP): Improves platelet counts in adults with persistent or chronic ITP. - Severe aplastic anemia: Supports platelet recovery when used with immunosuppressive therapy. - Hepatitis C‑related thrombocytopenia: Helps raise platelet numbers in patients undergoing antiviral therapy. - Myelodysplastic syndromes (MDS) with severe thrombocytopenia: Used experimentally; clinical benefit may include higher platelet counts.

Eltrombopag may cause a range of adverse reactions, most of which are dose‑dependent and reversible upon discontinuation.

Common Side Effects: - Nausea: Mild to moderate gastrointestinal upset. - Diarrhea: Loose stools, often transient. - Headache: Tension‑type or mild migraine‑like pain. - Fatigue: Generalised tiredness without clear cause. - Elevated liver enzymes: Mild increases in ALT/AST.

Serious or Rare Side Effects: - Hepatotoxicity: Significant liver injury requiring monitoring. - Thromboembolic events: Deep‑vein thrombosis or pulmonary embolism. - Bone marrow fibrosis: Rare progression of marrow scarring. - Severe allergic reaction: Anaphylaxis or angioedema. - Vision changes: Rare retinal pigment epithelium alterations.

When prescribing Eltrombopag, clinicians should consider several safety measures and patient‑specific factors.

- Liver function monitoring: Check ALT/AST before starting and periodically during therapy. - Pregnancy and lactation: Use only if the potential benefit outweighs risk; data are limited. - Concomitant anticoagulants: Assess bleeding risk and adjust therapy as needed. - Iron deficiency: Correct before initiating therapy to optimise response. - Renal impairment: Dose may need adjustment in severe renal dysfunction. - Store at below 25°C: Keep in the original container, protect from moisture and direct sunlight.

Eltrombopag interacts with several medicines that can alter its absorption or increase toxicity.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: Reduce oral absorption of Eltrombopag. - Ciprofloxacin and other fluoroquinolones: May increase serum concentrations. - Cyclosporine: Elevates risk of hepatotoxicity.

Moderate Interactions (Monitor Closely): - Warfarin: May affect INR values; monitor coagulation parameters. - Oral contraceptives: Potentially reduced efficacy; consider alternative contraception. - Statins (especially simvastatin): May increase risk of liver enzyme elevation.